Sodium-glucose co-transporter 2 inhibitor therapy reduces the administration frequency of anti-vascular endothelial growth factor agents in patients with diabetic macular oedema with a history of anti-vascular endothelial growth factor agent use: A cohort study using the Japanese health insurance claims database期刊界 All Journals 搜尽天下杂志传播学术成果专业期刊搜索期刊信息化学术搜索

Sodium-glucose co-transporter 2 inhibitor therapy reduces the administration frequency of anti-vascular endothelial growth factor agents in patients with diabetic macular oedema with a history of anti-vascular endothelial growth factor agent use: A cohort study using the Japanese health insurance claims database

Authors:	Ryoichi Ishibashi MD Yosuke Inaba PhD Masaya Koshizaka MD Yoko Takatsuna MD Tomoaki Tatsumi MD Yuki Shiko ME Yusuke Kashiwagi MD Yoshiro Maezawa MD Yohei Kawasaki PhD Eiryo Kawakami MD Shuichi Yamamoto MD Koutaro Yokote MD

Affiliation:	1. Department of Medicine, Division of Diabetes, Endocrinology and Metabolism, Kimitsu Chuo Hospital, Kisarazu, Japan;2. Clinical Research Center, Chiba University Hospital, Chiba, Japan;3. Department of Endocrinology, Hematology, and Gerontology, Chiba University Graduate School of Medicine, Chiba, Japan;4. Department of Ophthalmology, Chiba Rosai Hospital, Ichihara, Japan Department of Ophthalmology and Vision Science, Chiba University Graduate School of Medicine, Chiba, Japan;5. Department of Ophthalmology and Vision Science, Chiba University Graduate School of Medicine, Chiba, Japan;6. Department of Artificial Intelligence Medicine, Chiba University Graduate School of Medicine, Chiba, Japan

Abstract:

Keywords:	diabetic retinopathy real-world evidence SGLT2 inhibitor type 2 diabetes